Method for treating triple-negative breast cancer using AMPI-109
AssigneesThe Regents of the University of Colorado, a body corporate, Trustees of Boston University
InventorsHamid Gari, Jim Lambert, Scott Lucia, Rahul Ray, Ann Thor
Life of this patent
Estimating the term…
Abstract
A targeted approach toward the treatment of TN breast cancer by using AMPI-109 is disclosed. AMPI-109 is a compound with remarkable “cancer-specific” characteristics. In particular, AMPI-109 demonstrates a striking targeted capability to inhibit the proliferation of TN breast cancer cells and to induce apoptosis in TN breast cancer cells. The growth inhibitory effect of AMPI-109 is independent of VDR. AMPI-109 can also be coupled with other oncolytic agents in treating a patient with TN breast cancer.
Claims5
A method for treating triple-negative breast cancer, comprising:
- administering a drug comprising AMPI-109 in an amount effective for treating or preventing triple-negative breast cancer to a patient in need thereof, wherein AMPI-109 has a chemical structure of
Dependencies are inferred from the claim text.